NICE’s Forxiga Reversal For Diabetes 2 Restricts Treatment Regimens
This article was originally published in The Pink Sheet Daily
Reversing a previous stance, NICE has now agreed to recommend BMS/AZ’s Forxiga for diabetes type 2, though questions concerning data on combination regimens led to restrictions.
You may also be interested in...
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.